Method and composition for the treatment of lipid and glucose metabolism disorders

Abstract

Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D 1 dopamine agonist in conjunction with a dopamine D 2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D 1 dopamine agonist and the D 2 dopamine agonist is conducted at a predetermined time.

What is claimed is:  
     
         1 . A method for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate animal subject in need of such modification or regulation a D 1  dopamine agonist in conjunction with a dopamine D 2  agonist wherein the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein.  
     
     
         2 . The method of    claim 1    wherein the D 2  agonist is an ergot alkaloid is selected from the group consisting of 2-bromo-alpha-ergocriptive, 6-methyl 8 beta-carbobenzyloxyaminoethyl-10-alpha-ergoline, 8-acylaminoergoline, pergolide, lisuride, 6-methyl-8-alpha-(N-acyl) amino-9-ergoline, 6-methyl-8-alpha-(N-phenyl-acetyl)amino-9-ergoline, ergocomine, 9,10-dihydroergocomine, and D-2-halo-4-alkyl-8-substituted ergolines, D-2-bromo-6-methyl-8-cyanomethylergoline.  
     
     
         3 . The method of    claim 1    wherein the D 1  agonist comprises SKF38393.  
     
     
         4 . The method of    claim 2    wherein the ergot alkaloid comprises bromocriptine.  
     
     
         5 . The method of    claim 1    wherein the D 2  agonist is administered at a predetermined time of day.  
     
     
         6 . The method of    claim 5    wherein the D 1  agonist is administered at about the same time as the D 2  agonist.  
     
     
         7 . A method for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate animal subject in need of such modification or regulation a D 1  agonist in conjunction with at least one member selected from the group consisting of an adrenergic α 1  antagonist, an adrenergic α 2  agonist and a serotonergic inhibitor wherein the amount of the combination is sufficient to effect at least one of the following lipid and glucose metabolic indices: body weight, body fat, circulating insulin, plasma or blood glucose, plasma lipid and plasma lipoprotein.  
     
     
         8 . The method of    claim 7    wherein the D 1  agonist and the member of said group is administered at a predetermined time of day.  
     
     
         9 . The method of    claim 8    wherein the D 1  agonist is administered at about the same time as member of said group.  
     
     
         10 . A method for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate animal subject in need of said modification or regulation a D 1  agonist in conjunction with at least one of a α 2  agonist, a α 1  antagonist and a serotonergic inhibitor, and further in conjunction with a D 2  agonist sufficient to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid.  
     
     
         11 . A therapeutic agent combination for modifying or regulating at least one of glucose and lipid metabolism disorders comprising: 
 a first amount of a dopamine D 1  agonist; and    a second amount of at least one member selected from the group consisting of: 
 (i) a dopamine D 2  agonist; and  
 (ii) at least one of an adrenergic α 1  antagonist, an adrenergic α 2  agonist and a serotonergic inhibitor.  
   
     
     
         12 . A method for modifying or regulating at least one of glucose or lipid metabolism disorders comprising: 
 administering to a subject in need of said modification or regulation: 
 (i) a D 2  agonist in a first amount; and  
 (ii) at least one of an adrenergic α 1  antagonist, an adrenergic α 2  agonist and a serotonergic inhibitor in a second amount;  
 said first and second amounts being sufficient to improve at least one of the following indices of glucose or lipid metabolism: body weight, body fat, plasma insulin, plasma glucose and plasma lipid.